Epidermolysis Bullosa Global Clinical Trials Review, H1, 2017

2017-03-31
Price :
Published : Mar-2017
No. of Pages : 67

Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials 13
Clinical Trials by Phase in G7 Countries 14
Clinical Trials in G7 Countries by Trial Status 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Epidermolysis Bullosa Therapeutics Clinical Trials 23
Prominent Drugs 24
Latest Clinical Trials News on Epidermolysis Bullosa 25
Mar 06, 2017: Castle Creek Pharmaceuticals Announces Presentation of Phase 2 Clinical Data for Diacerein 1% Ointment in Treatment of Epidermolysis Bullosa Simplex 25
Mar 06, 2017: Amryt Pharma Announces AP101 trial discussions completed with FDA & EMA 25
Feb 27, 2017: RegeneRx Licensee Receives FDA Permission to Conduct a Phase 3 Trial of RGN-137 for Epidermolysis Bullosa in U.S. 25
Clinical Trial Profile Snapshots 27
Appendix 64
Abbreviations 64
Definitions 64
Research Methodology 65
Secondary Research 65
About GlobalData 66
Contact Us 66
Source 67

List of Tables

Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region, 2017* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries, 2017* 11
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 12
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2017* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase, 2017* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 17
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2017* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2017* 19
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 20
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 22
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 23
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 24

List of Figures

Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Region (%), 2017* 6
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 7
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 8
Epidermolysis Bullosa Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017* 9
Epidermolysis Bullosa Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 10
Epidermolysis Bullosa Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 11
Epidermolysis Bullosa Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 12
Proportion of Epidermolysis Bullosa to Dermatology Clinical Trials, G7 Countries (%), 2017* 13
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 14
Epidermolysis Bullosa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 15
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Phase (%), 2017* 16
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 17
Epidermolysis Bullosa Therapeutics, Global, Clinical Trials by Trial Status, 2017* 18
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, by End Point Status, 2017* 19
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 20
Epidermolysis Bullosa Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 21
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 22
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 23
Epidermolysis Bullosa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 24
GlobalData Methodology 65

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData